載入...

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e., exon 19 deletions or L858R). However, acquired resistan...

全面介紹

Na minha lista:
書目詳細資料
發表在:Expert Rev Anticancer Ther
Main Authors: Gao, Xin, Le, Xiuning, Costa, Daniel B.
格式: Artigo
語言:Inglês
出版: 2016
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940973/
https://ncbi.nlm.nih.gov/pubmed/26943236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2016.1162103
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!